Nucleus and ARTBIO Join Forces for Radioligand Therapies Production

• ARTBIO, Inc. and Nucleus RadioPharma Inc. have entered a strategic manufacturing and supply agreement.

• Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001.

ARTBIO a clinical-stage radiopharmaceutical company, and Nucleus RadioPharma an integrated development, manufacturing, and supply chain organisation for radiopharmaceuticals, have announced a strategic manufacturing and supply agreement. The partnership is set to bolster ARTBIO’s therapeutic product manufacturing capabilities.

Under the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001. The manufacturing will utilise ARTBIO’s AlphaDirect 212Pb isolation technology. This collaboration will enable the supply and manufacturing of ARTs from Nucleus’ facility in Rochester, MN, for patients living in the Northern and Midwest U.S.

Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO, said, “As we continue building our distributed manufacturing capabilities in the U.S. and globally, selecting partners who share our patient-centric vision is critical. The Nucleus team shares our passion to make targeted radiopharmaceutical therapies accessible, and together, we commit to bringing a new class of alpha radioligand therapies to hospitals across greater Minnesota and beyond.”

Charles S. Conroy, Chief Executive Officer of Nucleus, echoed Ostuni’s sentiments. He stated, “This strategic partnership with ARTBIO underscores our unwavering commitment to transforming the lives of cancer patients through groundbreaking therapies. We are thrilled to unite in our mission to address the pressing need for innovative radiopharmaceuticals, ensuring that patients have access to potentially life-changing treatments with highest quality and supply chain resilience.”

AlphaDirect, a first-of-its-kind system developed by ARTBIO, delivers highly pure 212Pb from widely available raw materials. 212Pb is an alpha-emitting radioisotope that has gained attention for its potential applications in therapeutic medicine, particularly in targeted alpha radioligand therapy due to the radioisotope’s attractive short half-life and other properties.